Background: Proteomic approaches identifying biomarkers have been applied to asthma to only 30
INTRODUCTION 52 53
Asthma is a lung disease which features chronic inflammation, episodic bronchospasm, airway 54 hyper responsiveness, and airway remodeling [reviewed in Elias et al. (1 ) ], and is a serious 55 public health problem worldwide. The pathobiology remains relatively obscure. Studies have 56 identified associations of asthma with variants in various genes [reviewed in Vercelli (2) ], but 57 these account for only a small portion of the familial inheritance patterns. The emerging area of 58 plasma proteomics holds promise for biomarker discovery in complex diseases. Thus far 59 plasma proteomic methodologies have been applied to the study the biology of asthma to only a 60
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Quantitation of the candidate proteins identified by antibody array screening was performed 105 using Quantikine ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's 106 instructions. Sample size of asthma group (our study being longitudinal) could be expanded 107 to18 samples and included all of the subjects in the IIS population who both met the criteria for 108 persistent childhood asthma (n=33) and had sufficient samples at age 3 for analysis. The non-109 asthma group was increased to 54 (3 times larger than the asthma group) randomly selected 110 from among 146 in the IIS population who met the criteria and had sufficient samples at age 3. 111
Samples were run as 2-4 replicates and values below the lowest standard were assigned one-112 half the lowest standard. For proteins with less than 15% undetectable values, distributions of 113 values were assessed for normality and if skewed to the right were log transformed. Groups 114 were compared by Student's two-sample t test. For proteins with greater than 15% undetectable 115 values, groups were compared using Mann-Whitney comparison of medians. Odds ratios with 116 mutual adjustment were calculated to assess independence of the associations between two 117 protein biomarkers and asthma. Proteins differing by asthma status were further assessed by 118 dividing the asthma group into those diagnosed by or after age 3. These groups were 119 compared by ANOVA and post-hoc Fisher's protected LSD test. A p-value <0.05 was 120 considered significant. 121
122
Blood samples were assayed for hemoglobin by Sonora Quest Laboratories (Tucson, AZ). Total 123 IgE values at 3y were available from assays previously run by Immulite 2000 as previously 124
described (8). 125

Identification of Plasma Protein Candidate Biomarkers for Childhood Asthma through 129
Antibody Arrays 130
In comparing the asthma (n=11) and non-asthma (n=12) groups based on the ranks of intensity 131 values from the antibody array assays, 4 proteins were identified as differentiating the two 132 groups (FDR adjusted p-value <0.1; Figure 1 ). The mean ranks of erythropoietin (EPO) and 133 galectin-3 were lower and the mean ranks of eotaxin-3 and soluble GP130 (sGP130) were 134 higher in the asthma compared to the non-asthma group. The 444 proteins assessed are listed 135 in E Table 1 or http://www.raybiotech.com/l-series-507-label-based-human-array-1-membrane-2.html. 136
137
Quantitation of Candidate Biomarkers for Childhood Asthma 138
In the enlarged sample set, we quantified by ELISA each of the four plasma proteins that were 139 identified by rank analysis in the antibody arrays. EPO had a lower mean log concentration in 140 the asthma compared to the non-asthma group (Figure 2A ). The direction of change agreed 141 with that of the rank differences in the antibody array. Also in accord with rank difference 142 direction, mean concentrations of sGP130 were increased in the asthma group ( Figure 2B) . 143
Mean galectin-3 concentrations did not differ significantly between the two groups ( Figure 2C) . 144
For eotaxin-3, for which 55% had at least one undetectable value, a nonparametric comparison 145 indicated there was no difference in median values between the asthma and non-asthma 146 groups (data not shown). Limiting the analysis to those samples also assayed in the antibody 147 array revealed a similar significant difference in the two groups for EPO although the difference 148 for sGP130 was not significant. 149
150
When modeled together, logistic regression analysis revealed the independence of the 151 associations of EPO and sGP130 plasma levels for asthma risk (Table 1) . Levels for these two 152 plasma biomarkers did not correlate with each other (r=0.12, p=0.33). Total IgE, well known to 153 be increased in asthma, was increased in the plasma samples of the children with asthmacompared to those without asthma (mean log±SEM: 1.775±0.141 vs. 1.104±0.089 IU/ml, 155 respectively, p<0.001). Total IgE correlated inversely with EPO (r=-0.36; p=0.002, n=70) but not 156 with sGP130 (r=-0.19; p=0.14, n=66). Hemoglobin levels did not differ by asthma group, 157 although levels in the combined groups tend toward their known inverse relation with p=0.07) . 159
160
In a post-hoc analysis, the asthma group was subdivided into those who had a diagnosis of 161 asthma already by the age of 3 and those who gained their diagnosis after age 3. A 162 concentration response was evident with lower levels of EPO in those already diagnosed at age 163 3 (Table 2 ). Similar stepwise increases were observed for total IgE. In contrast, sGP130 levels 164 did not differ by age of diagnosis in the asthmatic children. 165
166
Relation of plasma protein biomarkers to early life asthma risk factors 167
Eczema and wheezing in the first year of life are well-established, independent risk factors for 168 childhood asthma (9) and in the subset of IIS children show odds of more than 5 and 9 169 respectively (Table 3) . Interestingly, the mean log plasma EPO was lower in children with 170 eczema in the first year of life but was unrelated to first year wheezing (Table 4 ). In contrast, 171 mean sGP130 showed no relation to eczema but was higher in the children with first year 172 wheezing (Table 4) . Maternal asthma, also a significant risk factor for asthma in this subset, 173 was unrelated to either plasma protein biomarker (data not shown). 174 175 DISCUSSION 176
177
Our study identified four candidate protein biomarkers of asthma development using rank 178 analysis of 444 proteins by antibody array in plasma samples obtained at age 3 from a subsetidentified quantitative differences by ELISA for two: EPO had lower mean levels in the asthma 181 compared to the non-asthma group and sGP130 had higher levels in the asthma group. Neither 182 eotaxin-3 nor galactin-3 yielded quantitative differences between the two groups. 183 184 Plasma proteomics offers the opportunity to follow hypothesis generating approaches to study 185 of the biology of a complex disease like asthma. Differences in plasma proteins so identified 186 suggest that the disease may have systemic involvement (in contrast to being completely organ 187 constrained). Given that plasma contains several thousand proteins (10), antibody arrays do 188 not assess the entire protein spectrum and carry some bias in regard to limitations based on 189 availability of antibody pairs for protein detection. In contrast, though, they are much less limited 190 by relative concentrations than are mass spectrometry-based methods. reported 3 analytes (CXCL10, CCL17, CCL22) that differed between children who subsequently 205 gained a diagnosis of asthma by age 6 and those who did not. Although these analytes wereamong the 444 we assessed in the antibody array employed herein, they did not show a 207 difference related to asthma in our study, possibly related to differences in study design. 208
Reubsaet et al. studied only children with a history of early life wheezing, required evidence of 209 allergic sensitization for a diagnosis of asthma, and included no consideration for multiple 210 comparisons. Thus, it is possible that their findings may relate to an allergy susceptible group 211 within asthma. 212 213 ELISA for plasma EPO levels provided quantitative validation of the rank differences and agreed 214 in direction with data generated by antibody array. Thus, decreased concentration of EPO in 215 plasma at age 3 appears to serve as a biomarker differentiating subjects with asthma from 216 those without. The quantitative differences were greatest in children who had already acquired a 217 diagnosis of asthma by age 3. 218
219
Although EPO has long been known for its actions in increasing production of red blood cells, 220 other effects noted more recently involve protective effects on various cell types and include 221 anti-inflammatory (11-13), anti-apoptotic (14, 15), and antioxidant effects (16, 17) . levels of EPO associated with asthma shown in our study may increase risk for cell damage and 237 also show a need for future studies to examine the local airway milieu for differences in EPO. 238 239 Soluble GP130 has also not been clearly associated with asthma or early life wheeze, but such 240 roles are not without plausibility as sGP130 participates in a complex network with a membrane-241 bound form of GP130 together with IL-6 and both soluble and membrane-bound IL-6R (25). 242 sGP130 is suggested to serve as a natural inhibitor of IL-6 (26) and its inflammatory activity. 243
Soluble IL6R was shown (27) increased in airways of asthmatics. 244
245
We confirm that eczema and wheezing are associated independently with risk for asthma, 246 suggesting that they may identify distinct paths to asthma. In this regard, our two biomarkers 247 align differentially with these two risk factors: low plasma EPO levels associate with eczema in 248 the first year of life whereas high sGP130 associate with wheeze. Further studies are needed to 249 explore the possibility that the two biomarkers may mark separate paths involved in asthma 250
development. 251 252
Previous reports, differ as to whether eotaxin-3 is increased in asthma (28, 29). Our results 253 could not corroborate an increased plasma level associated with asthma. Galectin-3, has been 254 reported to function as a soluble receptor for IgE (30), but has not been clearly associated with 255 asthma and we were unable to identify differences in plasma levels between our asthma and 256 non-asthma groups. 257
Our study has several advantages: the use of samples from a non-selected birth cohort that 259 has longitudinal detailed information on respiratory symptoms and age of acquiring asthma 260 diagnoses; a broad, hypothesis-generating, screening approach to identifying candidate plasma 261 biomarkers; and a step validating the screening results through quantitation. A limitation of our 262 study is a relatively small sample size and thus other markers in the antibody array may be 263 present differentially in asthma but such differences were not detected because of insufficient 264
power. 265 266
In summary, our study demonstrates the utility of antibody array as a screening tool for 267 proteomic identification of candidate biomarkers in human plasma for childhood asthma and the 268 importance of quantitation for follow-up of candidates so identified. We suggest that children 269 with asthma have decreased levels of circulating EPO and increased levels of sGP130. In 270 addition, EPO relates to the early life risk factor, eczema, and sGP130 relates to early life 271 wheezing. Further studies are warranted to assess generalizability and to establish the 272 biological actions and possible therapeutic effects of treatment with EPO and/or 
